These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 31187511)

  • 1. Reply to "Serum Neurofilaments as Candidate Biomarkers of Natalizumab Progressive Multifocal Leukoencephalopathy".
    Dalla Costa G; Martinelli V; Furlan R; Comi G
    Ann Neurol; 2019 Aug; 86(2):324. PubMed ID: 31187511
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy.
    Loonstra FC; Verberk IMW; Wijburg MT; Wattjes MP; Teunissen CE; van Oosten BW; Uitdehaag BMJ; Killestein J; van Kempen ZLE
    Ann Neurol; 2019 Aug; 86(2):322-324. PubMed ID: 31192473
    [No Abstract]   [Full Text] [Related]  

  • 3. Rituximab versus fingolimod after natalizumab in multiple sclerosis: Also consider progressive multifocal leukoencephalopathy risk.
    Marignier R; Durand-Dubief F; du Pasquier R; Vukusic S
    Ann Neurol; 2016 Nov; 80(5):791. PubMed ID: 27554031
    [No Abstract]   [Full Text] [Related]  

  • 4. Metalloproteinase 9 as a biomarker of progressive multifocal leukoencephalopathy development in multiple sclerosis patients receiving natalizumab.
    Zahednasab H; Harirchian MH; Karampoor S; Keyvani H
    Ann Neurol; 2017 Oct; 82(4):647. PubMed ID: 28869674
    [No Abstract]   [Full Text] [Related]  

  • 5. Commentary on "Successful pregnancy after natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis".
    Arrambide G
    Mult Scler; 2017 Mar; 23(3):486-487. PubMed ID: 28260414
    [No Abstract]   [Full Text] [Related]  

  • 6. Progressive multifocal leukoencephalopathy associated to natalizumab extended dosing regimen.
    Hervás JV; Presas-Rodríguez S; Crespo-Cuevas AM; Canento T; Lozano-Sánchez M; Massuet-Vilamajó A; Ramo-Tello C
    Neurodegener Dis Manag; 2015 Oct; 5(5):399-402. PubMed ID: 26517599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended-interval dosing of natalizumab in NOVA - Authors' reply.
    Foley JF; Campbell N; Kong G
    Lancet Neurol; 2023 Mar; 22(3):200-201. PubMed ID: 36804085
    [No Abstract]   [Full Text] [Related]  

  • 8. Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.
    Vennegoor A; Rispens T; Van Oosten BW; Wattjes MP; Wondergem MJ; Teunissen CE; Van der Kleij D; Uitdehaag BM; Polman CH; Killestein J
    Mult Scler; 2015 Apr; 21(4):481-4. PubMed ID: 25078275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis.
    Lanza Cariccio V; Bramanti P; Mazzon E
    Mult Scler Relat Disord; 2018 Feb; 20():93-99. PubMed ID: 29353737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE
    Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended interval dosing strategies in multiple sclerosis: insights from natalizumab and ocrelizumab trials.
    Zid Y; Robertson NP
    J Neurol; 2024 Apr; 271(4):2141-2143. PubMed ID: 38436677
    [No Abstract]   [Full Text] [Related]  

  • 12. Extended-interval dosing of natalizumab in NOVA.
    Stüve O; Tugemann B
    Lancet Neurol; 2023 Mar; 22(3):199-200. PubMed ID: 36804084
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients.
    Dalla Costa G; Martinelli V; Moiola L; Sangalli F; Colombo B; Finardi A; Cinque P; Kolb EM; Haghikia A; Gold R; Furlan R; Comi G
    Ann Neurol; 2019 Apr; 85(4):606-610. PubMed ID: 30761586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asymptomatic progressive multifocal leukoencephalopathy during natalizumab therapy with treatment.
    Fabis-Pedrini MJ; Xu W; Burton J; Carroll WM; Kermode AG
    J Clin Neurosci; 2016 Mar; 25():145-7. PubMed ID: 26541323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 'across the pons' sign: A possible novel radiographic finding in natalizumab-associated progressive multifocal leukoencephalopathy.
    Budhram A; Pelikan JB; Kremenchutzky M; Sharma M
    J Neurol Sci; 2017 Apr; 375():304-306. PubMed ID: 28320156
    [No Abstract]   [Full Text] [Related]  

  • 16. Progressive multifocal leukoencephalopathy in the era of new disease-modifying treatments for multiple sclerosis.
    Filippi-Arriaga F; Riera-Arnau J; Rodríguez-Acevedo B; Bosch Ferrer M
    Med Clin (Barc); 2021 May; 156(10):509-514. PubMed ID: 33431183
    [No Abstract]   [Full Text] [Related]  

  • 17. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
    Soilu-Hänninen M; Päivärinta M; Sonninen P; Parkkola R; Vuorinen T; Erälinna JP
    Duodecim; 2013; 129(7):765-70. PubMed ID: 23720945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing understanding of individual risk and symptoms of progressive multifocal leukoencephalopathy in patients prescribed natalizumab for multiple sclerosis.
    Rath L; Vijiaratnam N; Skibina O
    Intern Med J; 2017 Feb; 47(2):194-199. PubMed ID: 27862809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational Neuroimmunology.
    Shirani A; Stüve O
    J Immunol; 2017 Feb; 198(4):1381-1386. PubMed ID: 28167648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations.
    Warnke C; Hartung HP
    Mult Scler; 2017 Jun; 23(7):920-922. PubMed ID: 28481191
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.